CORBUS PHARMACEUTICALS HOLDINGS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.24 USD | -2.69% |
|
+7.33% | +663.91% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Corbus Pharmaceuticals' ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48.55
USD
Average target price
71
USD
Spread / Average Target
+46.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +663.91% | 510M | |
| +7.64% | 115B | |
| +12.74% | 107B | |
| -13.27% | 22.31B | |
| -3.99% | 21.6B | |
| -6.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.85% | 14.26B | |
| +32.78% | 12.37B | |
| -28.20% | 8.28B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Transcript : Corbus Pharmaceuticals Holdings, Inc., Q1 2019 Earnings Call, May 09, 2019
